Quantcast

Latest TroVax Stories

2011-11-11 06:49:33

(Ivanhoe Newswire) — Treatment with a recombinant poxviral vaccine showed a positive response in both metastatic breast cancer and ovarian cancer, according to this study. "With this vaccine, we can clearly generate immune responses that lead to clinical responses in some patients," lead researcher, James Gulley, M.D., Ph.D., director and deputy chief of the clinical trials group at the Laboratory of Tumor Immunology and Biology at the National Cancer Institute, was quoted as saying....

2011-10-13 09:38:22

African-American patients with resected stage II and stage III colon cancer experienced worse overall and recurrence-free survival compared to whites, but similar recurrence-free intervals, according to a study published Oct. 12 in the Journal of the National Cancer Institute. Colorectal cancer is a leading cause of cancer-related deaths in the United States. In 2006, there were an estimated 146,970 new cases of colorectal cancer diagnosed in the U.S. Of those diagnosed, 15,000 were...

2011-08-18 08:00:00

WORCESTER, Mass. and TORONTO, Aug. 18, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) announced today that the Company's wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com) presented an update of the ongoing Phase 2 trial with an off-the-shelf immunotherapeutic cancer vaccine, AE37, in patients with breast cancer at Cambridge Healthtech Institute's Sixth Annual ImVacS: The Immunotherapeutics and Vaccine Summit held August 16-18,...

2011-08-10 07:46:00

BETHESDA, Md., Aug. 10, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) reminded markets, in response to recent investor concerns about Dendreon's Provenge immune therapy, that NWBT's DCVax® immune therapies for a broad range of cancers (including prostate, brain, ovarian and others) hold the promise, based on available data to date, of being cost effective and priced below other immune therapies while still providing substantial profit margins for the...

2011-08-02 08:00:00

WORCESTER, Mass. and TORONTO, Aug. 2, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) is pleased to provide its shareholders with a corporate update of developments that have been achieved since the appointment of Mark Fletcher as President & Chief Executive Officer on September 29, 2010. "Since my appointment as President & Chief Executive Officer of Generex, I have made it a priority to proactively communicate significant catalysts to the...

2011-06-15 02:00:00

TUEBINGEN, Germany, June 15, 2011 /PRNewswire/ -- igoommatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma (RCC). The trial is designed to demonstrate the overall survival benefit of IMA901 in...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related